Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin + gemcitabine second-line treatment in platinum-sensitive advanced ovarian cancer
2006-002116-10Phase 2Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Nov 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and gemcitabine in ovarian cancer and epithelial ovarian cancer (EOC), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoints: Myelotoxicity and Objective tumor response rate. Started Nov 2006; status: completed.
02
Drugs
carboplatingemcitabine
03
Conditions
ovarian cancerepithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2006-002116-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002116-10.